1. Early Diagnosis and Management of SSc-ILD

2. What Is SSc-ILD?

3. SSc-ILD Is a Shared Disease for Rheumatologists and Pulmonologists

4. Diagnosing ILD in Patients With SSc

5. ILD Is the Leading Cause of Death Related to SSc

6. How Should Pulmonologists and Rheumatologists Approach SSc-ILD?

7. Epidemiology of SSc in Patients With ILD

8. Diagnosis of SSc-ILD

9. High Resolution CT Imaging

10. A Simple Staging System to Predict Prognosis

11. Diagnosis of SSc-ILD: Summary

12. Management of SSc-ILD

13. Scleroderma Lung Study I Oral Cyclophosphamide vs Placebo

14. Tolerability of Oral Cyclophosphamide

15. Scleroderma Lung Study II Mycophenolate Mofetil vs Oral Cyclophosphamide

16. Combination Prednisone and Mycophenolate Mofetil

17. Current Approach to Treatment of SSc-ILD

18. Potential Future Approaches to Treatment of SSc-ILD?

19. LOTUSS Trial Pirfenidone

20. Scleroderma Lung Study III Pirfenidone With Mycophenolate Mofetil

21. SENSCIS Trial Nintedanib

22. SENSCIS Trial Key Eligibility Criteria

23. SENSCIS and IMPULSIS Trials Annual Rate of Decline in FVC

24. SENSCIS Trial Secondary Endpoints

25. SENSCIS Trial Tolerability -- Most Frequent Adverse Events

26. Treatment Strategies: Summary

27. Evaluating Treatment Response

28. Collaboration With Multidisciplinary Care

29. Abbreviations